Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matt Kalaycio

Showing results (71-80 of 155) with videos related to

Pageof 16
Sort By:
Cancer|December 20, 2011
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF)Nelli Bejanyan, Ramon V Tiu, Azra Raza, et al.
British Journal of Haematology|January 13, 2011
The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controlsBrian T Hill, Lisa Rybicki, Brian J Bolwell, et al.
American Journal of Hematology|October 15, 2013
Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemiaMoshe C Ornstein, Sudipto Mukherjee, Sanjay Mohan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 13, 2006
Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantationNavin Wadehra, Sherif Farag, Brian Bolwell, et al.
European Journal of Haematology|June 26, 2012
Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemiaAnna Brady, Sarah Gibson, Lisa Rybicki, et al.
Leukemia & Lymphoma|February 15, 2011
Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphomaBrian T Hill, Lisa Rybicki, Stephen Smith, et al.
British Journal of Haematology|October 30, 2010
Multiple unit umbilical cord blood transplantation with total body irradiation, etoposide and antithymocyte globulin for adult haematological malignancy patientsRonald M Sobecks, Edward Copelan, Matt Kalaycio, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 2, 2011
Risk factors for 30-day hospital readmission following myeloablative allogeneic hematopoietic cell transplantation (allo-HCT)Nelli Bejanyan, Brian J Bolwell, Aleksandr Lazaryan, et al.
British Journal of Haematology|March 8, 2011
Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL)Anjali S Advani, Sarah Gibson, Elizabeth Douglas, et al.
Journal of Clinical Apheresis|June 8, 2011
Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: a simple method using day 1 CD34+ cell yieldHien K Duong, Brian J Bolwell, Lisa Rybicki, et al.
Pageof 16

Showing results (71-80 of 155) with videos related to

Sort By:
Pageof 16
Cancer|December 20, 2011
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF)Nelli Bejanyan, Ramon V Tiu, Azra Raza, et al.
British Journal of Haematology|January 13, 2011
The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controlsBrian T Hill, Lisa Rybicki, Brian J Bolwell, et al.
American Journal of Hematology|October 15, 2013
Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemiaMoshe C Ornstein, Sudipto Mukherjee, Sanjay Mohan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 13, 2006
Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantationNavin Wadehra, Sherif Farag, Brian Bolwell, et al.
European Journal of Haematology|June 26, 2012
Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemiaAnna Brady, Sarah Gibson, Lisa Rybicki, et al.
Leukemia & Lymphoma|February 15, 2011
Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphomaBrian T Hill, Lisa Rybicki, Stephen Smith, et al.
British Journal of Haematology|October 30, 2010
Multiple unit umbilical cord blood transplantation with total body irradiation, etoposide and antithymocyte globulin for adult haematological malignancy patientsRonald M Sobecks, Edward Copelan, Matt Kalaycio, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 2, 2011
Risk factors for 30-day hospital readmission following myeloablative allogeneic hematopoietic cell transplantation (allo-HCT)Nelli Bejanyan, Brian J Bolwell, Aleksandr Lazaryan, et al.
British Journal of Haematology|March 8, 2011
Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL)Anjali S Advani, Sarah Gibson, Elizabeth Douglas, et al.
Journal of Clinical Apheresis|June 8, 2011
Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: a simple method using day 1 CD34+ cell yieldHien K Duong, Brian J Bolwell, Lisa Rybicki, et al.
Pageof 16